MetaMx™ is composed of novel, synthetic peptides that target and attach to BTICs and invasive glioma cells, for the purpose of imaging, diagnosis and developing targeted therapies to improve patient outcomes and survival rates among glioblastoma patients.
Treatment for antibiotic resistant lung and urinary tract infections
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for AB569 in the treatment of Pseudomonas aeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis.
Arch has developed a group of novel synthetic peptides and peptide conjugates that employ a novel chemistry (non-toxic, and environmentally friendly process) to react with solid surfaces such as metals, and plastics to generate new materials that display new surface properties.
Widespread application for the treatment of chronic diseases
As the population ages, the prevalence of chronic disease is on the rise and includes common conditions such as heart disease, diabetes, arthritis, inflammatory/infectious bowel disease and chronic kidney disease. The overall objective is to develop new diagnostic tests or anti-inflammatory drugs that can be used to treat humans with these common chronic diseases.